Disc Medicine, Inc.

NASDAQ:IRON

Biotechnology

Healthcare
$77.98 -0.03%

-$0.02 today

Market cap
$2.99B
Beta
2.10
P/E (TTM)
-11.2
EPS (TTM)
-$6.28
52W Low $40.00High $99.50

Volume 0.95M

Average 0.47M

IRON Long-term Debt

Borrowings due after more than one year.

Disc Medicine, Inc.NASDAQ: IRON

Long-term Debt · Q3 FY2026 · quarter ended Sep 2026

Long-term debt rises 106.4% from a year ago

Long-term debt stood at $59.75M at the end of Q3 FY2026, up 106.4% from a year earlier and up 0.7% from the prior quarter.

Context

  • Long-term debt amounted to 8.5% of total assets at the end of Q3 FY2026, up 3.9 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +106.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$59.75M+0.7% QoQ
Last fiscal yearDec 2025
$1.25M-95.6% YoY
Year agoSep 2025
$28.95M+106.4% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.4%——
1 year-95.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
1.25M USD
Year-over-year change
-95.6%
4-year CAGR
+32.7%

Long-term Debt vs competitors

How IRON compares with its peers on the latest reported figures

  • IRON's Sep 2026 long-term debt of $59.75M is the 2nd highest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of +106.4% is the highest of 3, against a peer median of +46.3%.
  • Long-term debt amounts to 8.5% of total assets for IRON, versus a peer median of 0.0%.
IRON Competitors Peer median
Long-term Debt for IRON and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GERNGeron CorporationMar 2026$230.22M +93.9%+97.2%43.1%
IRONDisc Medicine, Inc.Sep 2026$59.75M +106.4%—8.5%
DMRADamora Therapeutics, Inc.Mar 2026$1.34M -1.4%—0.3%
PTGXProtagonist Therapeutics, Inc.Jun 2026$0 ——0.0%
COAGHemab Therapeutics Holdings, Inc. Common StockJun 2026$0 ——0.0%
AGIOAgios Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
Peer median (excluding IRON) $0+46.3%+97.2%0.0%

Competitors are the stored peer set for IRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents88.04M194.61M360.38M192.43M91.15M
Short-term Investments000297.45M700.01M
Net Receivables00000
Inventory00000
Other Current Assets(802K)003.73M12.75M
Total Current Assets90.48M198.49M365.66M493.62M803.9M
Property, Plant & Equipment (Net)1.75M1.6M2.1M2.32M2.26M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets180K116K234K838K726K
Total Non-current Assets1.93M1.71M2.33M3.16M2.98M
Total Assets92.41M200.21M368M496.77M806.88M
Account Payables2.56M16.16M12.63M7.95M9.02M
Short-term Debt5M000611K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.45M3.62M5.79M7.21M27.01M
Total Current Liabilities13.42M22.58M21.44M23.32M36.64M
Long-term Debt404K0028.32M1.25M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities141.45M00029.16M
Total Non-current Liabilities143.19M1.03M1.44M29.87M30.41M
Total Liabilities156.61M23.61M22.88M53.19M67.05M
Common Stock02K2K3K4K
Retained Earnings(65.39M)(112.22M)(188.65M)(298M)(510.19M)
Accumulated OCI000289K965K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(64.2M)176.6M345.12M443.59M739.83M
Total Debt7.06M1.33M2.1M30M1.86M
Net Debt(80.98M)(193.28M)(358.28M)(162.43M)(89.28M)

Disc Medicine, Inc.

NASDAQ:IRON

Intrinsic Alpha fair value

Locked

Current Price

$77.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.